Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Carcinoma, Renal Cell 5Neoplasms 4Carcinoma, Hepatocellular 4Lung Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Ovarian Neoplasms 2Neoplasm, Residual 2NSCLC 2Kidney Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms, Second Primary 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Paclitaxel 115Carboplatin 114Cisplatin 46Topotecan 43Gemcitabine 31Cyclophosphamide 31Docetaxel 28Bevacizumab 28liposomal doxorubicin 27Filgrastim 20pembrolizumab 19Peripheral Blood Stem Cell Transplantation 18Taxes 15Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 13sargramostim 12olaparib 12Immunohistochemistry 11Chemotherapy, Adjuvant 11Surgical Procedures, Operative 10Therapeutics 9Flow Cytometry 9Etoposide 9oregovomab 8niraparib 8mirvetuximab soravtansine 8Psychiatric Rehabilitation 8Nivolumab 8Amifostine 8rucaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Tyrosine Kinase Inhibitors × Clear all
NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Zhongda Hospital

Phase 2 Unknown
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡